Biologics, Targeted Therapies Best for Acute PsA Dactylitis
METHODOLOGY:
In a prospective observational cohort, the median age of 1735 patients with PsA was 44.9 years, and 55% were men.
During a median follow-up of 12.1 years, dactylitis occurred in 753 (43.4%) patients and the remaining 982 (56.6%) never had it.
Among the patients with dactylitis, 295 (39.2%) were treated with nonsteroidal anti-inflammatory drugs (NSAIDs), 273 (36.3%) with conventional synthetic DMARDs, 100 (13.3%) with biologic or targeted synthetic DMARDs, 64 (8.5%) with glucocorticoid injection and a change in DMARD therapy, and 21 (2.8%) with glucocorticoid injection.
TAKEAWAY:
Univariable and multivariable analyses showed that the most significant clinical factors associated with acute PsA dactylitis included younger age, male sex, the presence of nail disease, a higher Clinical Disease Activity Index for Psoriatic Arthritis score and a higher modified Steinbrocker score for radiographic damage.
The median time to resolution of acute symptoms was 0.8 months.
Treatment with biologic or targeted synthetic DMARDs was associated with faster resolution of acute PsA dactylitis symptoms and longer time to recurrence than other therapies, including conventional synthetic DMARDs and NSAIDs.
One third of patients experienced recurrence of acute PsA dactylitis following treatment, with a median time to recurrence of 2 years.
IN PRACTICE:
'Acute dactylitis is common in about 43% of patients with psoriatic arthritis and considered a marker of disease severity, but we saw that treatment with biological or targeted DMARDS was associated with the best outcomes in terms of faster resolution of symptoms and prevention of recurrence,' Fadi Kharouf, MD, clinical research fellow at the University of Toronto/University Health Network, Toronto, Ontario, Canada, said in an interview.
SOURCE:
Kharouf presented the study at the Spondyloarthritis Research and Treatment Network (SPARTAN) 2025 Annual Meeting in Toronto, Ontario, Canada.
LIMITATIONS:
No limitations were reported.
DISCLOSURES:
The study was conducted as part of the Gladman Krembil Psoriatic Arthritis Program, which is supported by the Krembil Foundation and the Schroeder Arthritis Institute. Kharouf disclosed being supported by a fellowship from the Krembil Foundation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Beyond the Desk: Why WELL and Ergonomics Matter More Than Ever
NORTHAMPTON, MA / / August 11, 2025 / The way we work has changed. Offices now stretch from skyscrapers to spare bedrooms, and employee well-being is no longer just a nice-to-have experience, it's a business essential. But let's be honest: it's easy to overlook comfort when your "office" is your kitchen table. As hybrid and remote models become the norm, creating environments that support physical comfort and mental wellness is key. That's where smart ergonomics and the WELL Building Standard™ come in, not as extras, but as essentials. Together, they offer a roadmap to healthier, more engaged, and more productive teams. Ergonomics Isn't Just About Chairs Bad posture, poor lighting, and awkward setups, whether in the office or at home, can quickly lead to aches, strain, and burnout. And that hurts more than just your back. Productivity drops, engagement dips, and health costs rise. For example, research shows that poor ergonomics can reduce productivity by up to 40%, while proper ergonomic interventions can cut workers' compensation claims by 58%. A few quick fixes won't cut it anymore. This means going beyond merely providing furniture; it requires training, clear guidance, and a commitment to keeping all employees protected, comfortable, and productive, wherever they work. Today's hybrid work reality needs flexible, proactive ergonomic support, for everyone, everywhere. Enter: The WELL Building Standard What if your building could actually make people feel better? That's the idea behind the WELL Building Standard™, a globally recognized system that helps organizations create spaces designed to improve human health and well-being. WELL looks at the full picture of how a space affects the people inside it. That includes: Air quality and ventilation Lighting that supports natural rhythms Thermal comfort (because no one does their best work when they're freezing) Noise control, clean materials, water quality, and more Even mental health, community, and movement - it's all connected It's backed by science, designed to be flexible, and focused on people, whether you're designing a new space, upgrading an existing one, or just trying to better support hybrid teams. WELL certification comes in tiers: Silver (meeting core health and wellness features), Gold (demonstrating enhanced performance), and Platinum (achieving the highest level of human health and wellness benefits), but even starting the process shows employees you're serious about their health and comfort. And with options like the WELL Health-Safety Rating, you can focus on key operational strategies around cleanliness, emergency preparedness, and building trust, without a full design overhaul. Real Results: Some large global companies have reported that WELL-certified buildings led to 6% higher cognitive function scores and 16% better sleep quality among employees. Curious how WELL Certification could give your company an edge in attracting top talent?Explore this scenario that brings the benefits of WELL to life. Combining WELL-aligned workspaces and ergonomics support leads to a workplace that feels good to be in and one that stands out in a competitive market. Where Ergonomics and WELL Work Together Here's the best part: WELL and ergonomics aren't separate strategies - they're complementary. In fact, WELL includes specific features focused on ergonomic furniture and practices. Ergonomics is about physical comfort, reducing strain, and improving posture and productivity. WELL adds layers like air quality, lighting, noise control, and mental health support, all of which directly impact how people feel at work. Together, they reinforce each other. When ergonomic design is paired with WELL-aligned spaces, people experience less fatigue, more focus, and greater job satisfaction. And when employees feel good, they do better work. Real Results: The Benefits of WELL + Ergo Speak for Themselves Combining WELL strategies and ergonomic support isn't just about doing the right thing, it's about measurable business outcomes. For example: Fewer injuries: Think fewer neck, back, and wrist complaints. Better focus: Comfort + good air + smart lighting = clearer thinking. Happier teams: People feel valued, and they stick around. Bringing it to Life: What You Can Do Now Ready to start? Here are three practical steps to bring ergonomics and WELL principles into your workplace: Offer comprehensive ergonomics checks for both home and office setups: don't assume a one-size-fits-all solution works. Personalize support to help employees stay safe and comfortable wherever they work. Design with WELL in mind: natural light, quiet zones, thermal comfort, greenery, improved air filtration. Promote healthy habits through structured programs: encourage movement breaks every hour, provide hydration reminders, and create dedicated spaces for mental breaks and meditation. The Bottom Line: People-First Workplaces Win If you want a healthier, more productive workforce, it's time to think beyond the desk. Combine ergonomics with WELL principles and build work environments that support your people, wherever they are, so they feel safe and empowered to do their best work. Your employees will thank you. And your bottom line will too. Ready to transform your workplace wellness strategy? Our WELL-certified experts can guide you through a comprehensive assessment of your current environment and develop a customised roadmap for certification. Contact us today to schedule your initial consultation and discover how WELL certification can become your competitive advantage in attracting and retaining top talent. View additional multimedia and more ESG storytelling from Antea Group on Contact Info:Spokesperson: Antea GroupWebsite: info@ SOURCE: Antea Group View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
an hour ago
- Medscape
CPAP May Prevent BP Rise in Normotensive Sleep Apnea
TOPLINE: Among normotensive patients with severe obstructive sleep apnea (OSA) and a dipping blood pressure (BP) pattern, continuous positive airway pressure (CPAP) prevented increases in BP over a 3-month follow-up period, with significant reductions in nighttime diastolic BP compared with usual care. METHODOLOGY: Researchers conducted a randomized, prospective, controlled trial to assess the effect of CPAP on BP in normotensive individuals with severe OSA and a dipping BP pattern. Overall, 60 normotensive adult patients (mean age, 52.2 years; 66.7% men) with severe OSA (apnea-hypopnea index, ≥ 30 per hour) and a dipping BP pattern (reduction of ≥ 10% from daytime to nighttime BP) were randomly assigned to receive either CPAP or usual care for 12 weeks. Primary outcomes were changes from baseline to 3 months in ambulatory BP monitoring parameters: mean 24-hour BP; mean daytime and nighttime BP; 24-hour systolic and diastolic BP; and daytime and nighttime systolic and diastolic pressures. The secondary outcome was the change over 3 months in these ambulatory BP parameters according to adherence to CPAP, with a mean use of 4 or more hours per night defined as adequate adherence. TAKEAWAY: Over the study period, the CPAP group showed no significant change in ambulatory BP parameters, whereas the usual care group showed significant increases in 24-hour systolic BP, mean nighttime BP, and nighttime systolic and diastolic pressures. The CPAP group had a significantly greater reduction in nighttime diastolic BP than the usual care group (mean difference, -3.4 mm Hg; P = .015), but no other BP parameters differed significantly. Participants with inadequate adherence to CPAP had significantly greater increases in mean nighttime BP, nighttime systolic BP, and nighttime diastolic BP than those with adequate adherence. IN PRACTICE: 'Overall, this randomised trial provides novel insights into the potential benefits of CPAP therapy as a preventive measure for the development of hypertension. Further larger studies, including a greater proportion of women and potentially guided by polysomnography-based phenotypes, are needed to better understand the impact of OSA therapy in individuals with normal BP,' experts wrote in an accompanying editorial. SOURCE: This study was led by Adriano D.S. Targa and Gerard Torres, Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova-Santa Maria, Biomedical Research Institute of Lleida, Lleida, Spain. It was published online on July 24, 2025, in European Respiratory Journal. LIMITATIONS: The single-center design potentially limited the generalizability of the findings. The sample size was powered to detect a difference of ≥ 3 mm Hg, but the true effect in normotensive individuals with OSA may have been smaller, leaving the analysis underpowered. DISCLOSURES: This study was supported by the Instituto de Salud Carlos III, co-funded by the European Union, Sociedad Española de Neumología y Cirugía Torácica, and Diputació de Lleida. Some authors disclosed receiving financial support from Instituto de Salud Carlos III, co-funded by the European Union, and the Catalan Institution for Research and Advanced Studies Academia programme. The authors reported having no potential conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
an hour ago
- Medscape
49-Year-Old Patient's Pleomorphic Breast Relapse in Weeks
A 49-year-old woman with a history of bilateral breast cancer (right breast, cT2cN0M0, clinical stage IIA; left breast, cT2cN1M0, clinical stage IIB) presented with local recurrence in the right breast. Following neoadjuvant chemotherapy, the patient achieved a partial pathologic response and underwent breast-conserving surgery with axillary lymph node dissection and radiotherapy. After 6 years and 7 months, local recurrence in the right breast was identified, and the patient subsequently underwent mastectomy. However, 4 weeks later, metastasis to the contralateral breast was detected. An additional 13 weeks later, metastatic pleural tumours occupied approximately 70% of the thoracic cavity. Only detailed pathologic analysis revealed the underlying diagnosis of pleomorphic breast carcinoma. Nobuyuki Takemoto, MD, from the Department of Breast and Thyroid Surgery at Japan Medical Alliance East Saitama General Hospital in Satte, Japan, and colleagues documented the extremely rare case. The Patient and Her History The patient visited the hospital complaining of swelling and erosion of the right nipple. Her medical history included bilateral breast cancer diagnosed more than 6 years earlier. The right-sided tumour was the nonluminal type (oestrogen and progesterone receptor positive; HER2 3+; Ki-67, 31%), and the left-sided tumour was luminal A-like (oestrogen and progesterone receptor positive; HER2-; Ki-67, < 5%). As neoadjuvant chemotherapy, four cycles of adriamycin and cyclophosphamide (60/600 mg/m²) every 3 weeks, followed by paclitaxel (80 mg/m²) and trastuzumab (loading dose 4 mg/kg, maintenance 2 mg/kg) weekly for 12 weeks, were administered. The patient achieved a clinical partial response on imaging. Bilateral breast-conserving surgery and axillary lymph node dissection were performed. The pathologic evaluation of the therapeutic effect was grade 1 (right: ypT1bypN0M0, ypstageI; left: ypT1cypN0[i+]M0, ypstageI). After radiotherapy (50 Gy in 25 fractions) of the residual mammary gland, trastuzumab (6 mg/kg) was administered. However, the patient requested to discontinue treatment after two courses. She was subsequently followed with endocrine therapy (tamoxifen). Six years and 7 months after the initial operation, local recurrence occurred. Findings and Diagnosis On admission, all vital signs were within normal limits. Physical examination, including inspection, auscultation, palpation, and percussion, showed no abnormalities. Routine laboratory test results were unremarkable. A CT revealed a swollen right nipple. and three stump cytology tests for erosion were negative, but the nipple itself showed a tendency to grow, so a core needle biopsy (CNB) was performed. Pathologic findings showed invasive carcinoma and suggested metaplastic carcinoma. As no metastases to other organs were found, a right mastectomy was performed. After chemotherapy with carboplatin, radiation therapy to the supraclavicular fossa was planned; however, 4 weeks after the operation, a round mass of approximately 1 cm was found in the left breast. CNB revealed a suspicious malignant metaplastic carcinoma. It was determined that there was a high possibility of metastasis to the contralateral side, and a left mastectomy was performed. However, 12 weeks later, a left pleural tumour and a right chest wall mass appeared. After another 13 weeks, the left thoracic cavity was occupied by almost 70% of the pleural mass, and the right chest wall mass grew to 10 cm in size. Furthermore, the white blood cell count rose rapidly to 98.8 × 103/µL, with 94.8% neutrophils, 2.5% lymphocytes, and 1.8% monocytes. Bone marrow metastasis was suspected, but bone marrow aspiration could not be performed due to the patient's poor general condition. The patient died 25 weeks after the diagnosis of local recurrence. Pathologic examination revealed a pleomorphic carcinoma (PC) transitioning from ductal carcinoma, with a subtype of triple-negative breast cancer. Immunohistochemical staining showed positive expression of AE1/3 (anti-pan cytokeratin), beta-catenin, E-cadherin, and vimentin. Staining was negative for CAM5.2 (cytokeratin), HMB45 (human melanoma black 45), and LCA (leukocyte common antigen). Discussion 'When a rapidly growing breast mass is encountered, it is necessary to consider PC as one of diagnostic candidate. Little research has been done on PC, particularly on diagnosis and therapy. Thus, further case accumulation and analyses are awaited to gain more insight on the characteristics of PC,' the authors wrote.
